(Total Views: 528)
Posted On: 03/06/2021 1:13:54 PM
Post# of 153915
RTB,
We don't have all the information to make a good calculation. we are missing:
The exact split between SOC and VX
The total number of deaths.
We have some percentages. I choose those numbers because they conform with most of the percentages we were given, also, we need to take into account the last statement:
So, the number of deaths in SOC is larger rather than smaller. It would seem that 2-3 survivals in this arm is likely.
Also, if we take the AVERAGE discharged alive (28+11)/2=19.5% times 62 yields 12 patients discharged (around 50 deaths all together). That is why my "mortality" is larger
.
However, all of the above pure speculation, as you well point out, we are just "fitting" data to the percentages given.
We don't have all the information to make a good calculation. we are missing:
The exact split between SOC and VX
The total number of deaths.
We have some percentages. I choose those numbers because they conform with most of the percentages we were given, also, we need to take into account the last statement:
Quote:
Discharge alive: In addition, patients who received leronlimab demonstrated an improved probability of "discharged alive" at Day 28 (28% versus 11%), a 166% better rate than in the placebo group.
So, the number of deaths in SOC is larger rather than smaller. It would seem that 2-3 survivals in this arm is likely.
Also, if we take the AVERAGE discharged alive (28+11)/2=19.5% times 62 yields 12 patients discharged (around 50 deaths all together). That is why my "mortality" is larger
. However, all of the above pure speculation, as you well point out, we are just "fitting" data to the percentages given.
(1)
(0)
